Boehringer Ingelheim

Company snapshot

Boehringer Ingelheim maintains 193 tracked programs across Diabetes Mellitus, Type 2, Pharmacokinetic trial, Obesity, Pulmonary Disease, Chronic Obstructive, Asthma, Chronic Kidney Disease, Carcinoma, Non-Small-Cell Lung, Hypertension, Bronchiectasis, Hepatitis C, Atrial Fibrillation, Schizophrenia. Momentum score: 24/100 (30-day delta: n/a). Public registry data covers pipeline phase, clinical tr

• 193 active pipeline program(s) linked via ClinicalTrials.gov.
• 25 US patent(s) indexed to this assignee profile.
• 193 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Boehringer Ingelheim. Not investment advice.

• approval Jun 11, 2026

  CHMP backs nerandomilast for IPF and PPF in EU

• Peer + 0 momentum

  GSK Glaxo Smith

  TA overlap score 50

• Peer + 0 momentum

  Rhythm Pharmaceuticals Netherlands

  TA overlap score 44.6

• Peer + 0 momentum

  Takeda

  TA overlap score 40

• Peer + 0 momentum

  Novartis India

  TA overlap score 40

• Peer + 0 momentum

  Pfizer

  TA overlap score 39.6

• Peer + 0 momentum

  Sanofi Pasteur MSD

  TA overlap score 36.6

• Peer + 0 momentum

  Arrowhead Pharmaceuticals Ireland

  TA overlap score 32.6

• Peer + 0 momentum

  Eli Lilly and

  TA overlap score 32.4

• Peer + 0 momentum

  Vanda Pharmaceuticals Netherlands

  TA overlap score 32

• Peer + 0 momentum

  Janssen Cilag International

  TA overlap score 29.2

Recent activity

Latest pipeline, patent, and corporate events for Boehringer Ingelheim.

1. Jun 8, 2026 Clinical update

   1519-0001 — Phase 1

2. Jun 8, 2026 Clinical update

   1509-0007 — Phase 1

3. Jun 8, 2026 Clinical update

   1493-0008 — Phase 1

4. Jun 8, 2026 Clinical update

   1404-0009 — Phase 1

5. Jun 8, 2026 Clinical update

   1305-0039 — Phase 1

View all clinical trial activity →

• What is Boehringer Ingelheim?

  Boehringer Ingelheim is a pharma organization headquartered in Ingelheim am Rhein, DE. Primary therapeutic focus areas include Diabetes Mellitus, Type 2, Pharmacokinetic trial, Obesity, Pulmonary Disease, Chronic Obstructive, Asthma. NovaPharmaNews links 193 clinical program(s),

• Is Boehringer Ingelheim publicly traded?

  Boehringer Ingelheim appears in our database through regulatory marketing authorisation or clinical trial sponsor records; a US listed ticker is not shown for this entity.

• What drugs does Boehringer Ingelheim develop or market?

  We link 113 drug profile(s) where Boehringer Ingelheim is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/boehringer-ingelheim-international-gmbh#company-drugs.

• What are the latest developments for Boehringer Ingelheim?

  In the last 12 months our linked public records show 193 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does Boehringer Ingelheim focus on?

  Boehringer Ingelheim focuses on Diabetes Mellitus, Type 2, Pharmacokinetic trial, Obesity based on our analysis of their pipeline programs and drug development activities.